DOI: 10.6084/m9.figshare.26176660
title: Supplementary material: Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims

description: <b>These are peer-reviewed supplementary materials for the article '</b><b>Evaluation of inpatient and emergency </b><b>department healthcare resource utilization </b><b>and costs pre- and post-nusinersen for the </b><b>treatment of spinal muscular atrophy using </b><b>United States claims</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Figure 1: </b>Mean (SD) number of inpatient admissions per patient in individuals with SMA in the 12 months before and after nusinersen treatment. Mean (SD) number of days spent in hospital per patient in individuals with SMA in the 12 months before and after nusinersen treatment.<b>Supplementary Figure 2: </b>Mean (SD) ED visits and costs per patient in individuals with SMA in the 12 months before and after nusinersen treatment.<b>Supplementary Table 1: </b>Patient baseline characteristics of cohorts aligned with steps of patient selection criteria (who were ultimately excluded) in comparison to final cohort.<b>Aim:</b> Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. <b>Patients & methods:</b> Using the Merative™ MarketScan R ? Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (&lt;18 years) and adult (≥18 years). <b>Results:</b> Overall, 103 individuals treated with nusinersen were retained: 59 were pediatric (mean age [range]: 9 [1–17] years), and 44 were adults (30 [18–63] years). Inpatient admissions decreased by 41% for pediatrics and 67% for adults in the 12 months post-treatment versus the 12 months pre-treatment. Average inpatient admission costs per patient for the pediatric cohort decreased by 63% ($22,903 vs $8466) and by 79% ($13,997 vs $2899) for the adult cohort when comparing the 12 months pre-index with the 12 months post-index period. Total ED visits and ED visit costs decreased by 8% and 35%, respectively, for the overall cohort over the 12-month period pre- and post-index. <b>Conclusion:</b> Using US claims databases, nusinersen treatment in pediatric and adult patients was associated with reductions in HRU and costs over a 12-month period post-treatment initiation relative to the pre-treatment period.